On April 28, 2026, the Three-Year High-Quality Development Symposium of the Peking University Ningbo Institute of Marine Drugs, together with the PKU Medical and Life Health Project Roadshow Competition (Ningbo Station), was grandly held in Ningbo, Zhejiang. The event comprehensively reviewed the institute's three-year construction achievements, summarized development experience, and charted its development direction for the "15th Five-Year Plan" period. At the same time, focusing on cutting-edge fields such as biomedicine, health products, medical devices, precision instruments, and testing, it brought together social capital and industrial resources to select high-quality projects with industrialization prospects, injecting new momentum into the landing of high-quality PKU achievements in Ningbo and empowering the high-quality development of the regional life and health industry.

      Jiao Mingming, General Manager of Zhejiang Tianyuan Biotechnology Co., Ltd., and Dr. Chen Junjie, Chief Technology Officer, were invited to attend the event.

      Since its opening in 2023, the Peking University Ningbo Institute of Marine Drugs has produced fruitful results in scientific research cooperation, resource sharing, and industrial collaboration, jointly building an innovation ecosystem that benefits government, industry, academia, research, application, and capital. This three-year high-quality development symposium was both a concentrated showcase of past achievements and an important opportunity to deepen cooperation among all parties and promote project implementation.

      General Manager Jiao Mingming stated that Tianyuan Biotechnology has always been committed to promoting innovative development in the life and health industry and enjoys broad room for cooperation with the Peking University Ningbo Institute of Marine Drugs in scientific research cooperation and achievement translation. He noted that this invitation is a recognition of Tianyuan Biotechnology's technological strength and industry influence. Dr. Chen Junjie pointed out that the biopharmaceutical field is currently in a critical period of technological explosion and industrial transformation, with cutting-edge directions such as iPSC technology and cell therapy showing enormous potential. Through this roadshow competition, the company can exchange views with more innovative projects of clinical value and market prospects, and promote the rooting of cutting-edge technologies.

      The successful hosting of this event injected strong "PKU wisdom" and "Tianyuan strength" into the development of Ningbo's life and health industry. In the future, Tianyuan Biotechnology will continue to uphold an open and cooperative attitude, rely on national-level high-standard research platforms, deepen industry-academia-research integration, accelerate the translation of scientific and technological achievements, and strive to build Ningbo into a biopharmaceutical innovation hub with international influence, writing an even more brilliant chapter for the cause of human life and health.

      Founded in 2017, Zhejiang Tianyuan Biotechnology Co., Ltd. is a national high-tech enterprise dedicated to the integrated development of cell R&D, production, operations, and services. It holds valuable resource banks including an HLA umbilical cord matching bank, an iPS seed cell bank, and a tumor cell bank, and serves as a formulating unit for the group standard on immune function assessment methods under the National Health Commission. The company has jointly established a Metabolic and Immune Monitoring Joint Laboratory with the Institute of Science and Technology of the National Health Commission, and also serves as the Ningbo Storage Center of the National Stem Cell Translational Resource Bank and the Achievement Translation Center of the Institute of Science and Technology of the National Health Commission, among other important research and service platforms.